573 related articles for article (PubMed ID: 32616746)
1. Graves' disease.
Davies TF; Andersen S; Latif R; Nagayama Y; Barbesino G; Brito M; Eckstein AK; Stagnaro-Green A; Kahaly GJ
Nat Rev Dis Primers; 2020 Jul; 6(1):52. PubMed ID: 32616746
[TBL] [Abstract][Full Text] [Related]
2. HIV and ART related fat alterations.
Nat Rev Dis Primers; 2020 Jun; 6(1):49. PubMed ID: 32555271
[No Abstract] [Full Text] [Related]
3. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
Hou J; Tang Y; Chen Y; Chen D
Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
[TBL] [Abstract][Full Text] [Related]
4. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
5. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.
Kahaly GJ; Bartalena L; Hegedüs L; Leenhardt L; Poppe K; Pearce SH
Eur Thyroid J; 2018 Aug; 7(4):167-186. PubMed ID: 30283735
[TBL] [Abstract][Full Text] [Related]
6. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
7. TSH receptor specific monoclonal autoantibody K1-70
Furmaniak J; Sanders J; Sanders P; Li Y; Rees Smith B
Clin Endocrinol (Oxf); 2022 Jun; 96(6):878-887. PubMed ID: 35088429
[TBL] [Abstract][Full Text] [Related]
8. Management of Graves' hyperthyroidism: present and future.
Bartalena L; Piantanida E; Gallo D; Ippolito S; Tanda ML
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):153-166. PubMed ID: 35287535
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
10. Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance.
Bucci I; Giuliani C; Napolitano G
Front Endocrinol (Lausanne); 2017; 8():137. PubMed ID: 28713331
[TBL] [Abstract][Full Text] [Related]
11. Current insights into animal models of Graves' disease and orbitopathy.
Wiesweg B; Johnson KT; Eckstein AK; Berchner-Pfannschmidt U
Horm Metab Res; 2013 Aug; 45(8):549-55. PubMed ID: 23613015
[TBL] [Abstract][Full Text] [Related]
12. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
13. An Early Wave of Macrophage Infiltration Intertwined with Antigen-Specific Proinflammatory T Cells and Browning of Adipose Tissue Characterizes the Onset of Orbital Inflammation in a Mouse Model of Graves' Orbitopathy.
Philipp S; Horstmann M; Hose M; Daser A; Görtz GE; Jesenek C; Flögel U; Hansen W; Bechrakis N; Banga JPS; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2022 Mar; 32(3):283-293. PubMed ID: 34779257
[No Abstract] [Full Text] [Related]
14. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Horizons for Graves' Hyperthyroidism.
Lane LC; Cheetham TD; Perros P; Pearce SHS
Endocr Rev; 2020 Dec; 41(6):873-84. PubMed ID: 32845332
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
McLachlan SM; Rapoport B
Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease.
Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR;
Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507
[TBL] [Abstract][Full Text] [Related]
18. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
Trials; 2013 Apr; 14():119. PubMed ID: 23782950
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.
Sabini E; Ionni I; Rocchi R; Vitti P; Marcocci C; Marinò M
Eur Thyroid J; 2018 Jan; 7(1):51-54. PubMed ID: 29594055
[TBL] [Abstract][Full Text] [Related]
20. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
